A Study in Adult Patients With Major Depressive Disorder
This study has been completed.
Sponsor:
Eli Lilly and Company
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00795821
First received: November 19, 2008
Last updated: April 7, 2011
Last verified: April 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.
| Condition | Intervention | Phase |
|---|---|---|
|
Depressive Disorder, Major |
Drug: LY2216684 Drug: Placebo |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder |
Resource links provided by NLM:
Further study details as provided by Eli Lilly and Company:
Primary Outcome Measures:
- The Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Sheehan Disability Scale (SDS) [ Time Frame: 62 weeks ] [ Designated as safety issue: No ]
- Clinical Global Impressions of Severity Scale (CGI-Severity) [ Time Frame: 63 weeks ] [ Designated as safety issue: No ]
- The Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: 62 weeks ] [ Designated as safety issue: No ]
- The 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) [ Time Frame: 62 weeks ] [ Designated as safety issue: No ]
- The Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) [ Time Frame: 62 weeks ] [ Designated as safety issue: No ]
- The Euro-QoL Questionnaire - 5 Dimension (EQ-5D) [ Time Frame: 62 weeks ] [ Designated as safety issue: No ]
- The Fatigue Associated With Depression (FAs-D) Patient Reported Outcome (PRO) [ Time Frame: 62 weeks ] [ Designated as safety issue: No ]
- The Brief Fatigue Inventory (BFI) [ Time Frame: 62 weeks ] [ Designated as safety issue: No ]
- The Visual Analogue Scale for Fatigue (VAS-F) [ Time Frame: 62 weeks ] [ Designated as safety issue: No ]
- Resource Utilization Form [ Time Frame: 62 weeks ] [ Designated as safety issue: No ]
- The Columbia Suicide Severity Rating Scale (C-SSRS) [ Time Frame: 63 weeks ] [ Designated as safety issue: Yes ]
| Enrollment: | 495 |
| Study Start Date: | December 2008 |
| Study Completion Date: | March 2011 |
| Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 |
Drug: LY2216684
Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
Other Name: LY2216684
|
| Placebo Comparator: 2 |
Drug: Placebo
Dose: 3 tablets QD for 62 weeks
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adults age 18-65 years
- Meet criteria for MDD as defined by DSM-IV-TR criteria without psychotic features
- Women of child-bearing potential must test negative for pregnancy and agree to use a reliable method of birth control
- Grid Hamilton Rating Scale for Depression (GRID-HAMD17) total score >=18 at visit 1 and visit 2
- CGI-S score >=4 at visit 1 and visit 2
Exclusion Criteria:
- Are currently involved in or discontinued within the last 30 days from a clinical trial involving an off-label use of an investigational drug
- Have previously completed or withdrawn from this study or any other study investigating LY2216684
- Have had or currently have any additional ongoing DSM-IV-TR Axis 1 condition other than MDD
- Have had any anxiety disorder preceding the onset of depression that was considered the primary diagnosis within 1 year of visit 1
- Have an Axis II disorder which would interfere with compliance with the protocol
- Have a current or previous diagnosis of Bipolar I or II, psychotic depression, schizophrenia or other psychotic disorder
- Have a history of substance abuse within the past 1 year
- Women who are pregnant or breast-feeding
- Have had a lack of response of the current depressive episode to 2 or more adequate courses of antidepressant therapy, or in the judgement of the investigator considered to have treatment resistant depression
- Patients who are judged to be at serious suicidal risk
- Have a serious or unstable medical illness
- Have any diagnosed medical condition which could be exacerbated by noradrenergic agents including unstable hypertension, unstable heart disease, tachycardia or tachyarrhythmia, narrow angle glaucoma, or urinary hesitation or retention
- Have received treatment with a MAOI within 14 days prior to visit 1
- Have a history of severe allergies to more than 1 class of medication or multiple adverse drug reactions
- Have a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) or psychosurgery within the last year
- Have a history of any seizure disorder (other than febrile seizures)
- Require psychotropic medication other than sedative/hypnotic medication for sleep
- Have a thyroid stimulating hormone (TSH ) level outside the established reference range.
- Are taking or have received treatment with any excluded medication within 7 days prior to visit 2
- Initiation or change in intensity of psychotherapy or other non-drug therapies within 6 weeks prior to enrollment
- A positive urine drug screen for any substance of abuse at visit 1
- Have initiate or discontinued hormone therapy within the previous 3 months prior to enrollment
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00795821
Show 37 Study Locations
Show 37 Study LocationsSponsors and Collaborators
Eli Lilly and Company
Investigators
| Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
More Information
No publications provided
| Responsible Party: | Chief Medical Officer, Eli Lilly |
| ClinicalTrials.gov Identifier: | NCT00795821 History of Changes |
| Other Study ID Numbers: | 11313, H9P-MC-LNBI |
| Study First Received: | November 19, 2008 |
| Last Updated: | April 7, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Depressive Disorder Depression Depressive Disorder, Major |
Mood Disorders Mental Disorders Behavioral Symptoms |
ClinicalTrials.gov processed this record on May 16, 2013